23.06.2025 12:29

Novo Nordisk has terminated its partnership with Hims & Hers, a telehealth company, citing concerns about their sales and marketing practices related to the weight-loss drug Wegovy. This decision sent Hims & Hers' stock plummeting approximately 20% in pre-market trading.

Initially, Novo Nordisk had partnered with Hims & Hers and other telehealth platforms in April to broaden Wegovy's accessibility following the resolution of a U.S. supply shortage. This collaboration aimed to make the popular injectable medication more readily available to patients. However, the easing of the shortage also eliminated the legal loophole that had allowed compounding pharmacies to create and distribute cheaper, unapproved Wegovy alternatives.

The crux of Novo Nordisk's complaint lies in Hims & Hers' alleged violation of regulations prohibiting the large-scale distribution of compounded drugs under the pretext of personalized medicine. Novo Nordisk further levied accusations of deceptive marketing practices against Hims & Hers, asserting these actions jeopardize patient safety. The company's statement strongly suggests that Hims & Hers' actions were not in line with the agreed-upon terms and ethical standards.

Despite claims from telehealth companies that compounded versions of Wegovy remain necessary for patients with specific allergies or medical needs, Novo Nordisk has opted to sever ties with Hims & Hers. A response from Hims & Hers to CNBC's request for comment was pending at the time of this report. This termination underscores Novo Nordisk's commitment to safeguarding patient well-being and upholding regulatory compliance within the pharmaceutical industry.